Eun Dutasteride for AGA Trial: A Plain-English Overview of What It Established

At a glance

Field	Detail
N	917 Korean men with androgenetic alopecia
Intervention	Dutasteride 0.5 mg daily
Comparator	Finasteride 1 mg daily
Duration	24 weeks
Primary endpoint	Change in target-area hair count from baseline
Key result	Dutasteride 0.5 mg superior to finasteride 1 mg in hair count increase at 24 weeks

The Question This Trial Answered

By 2010, finasteride 1 mg had been the standard oral treatment for male pattern hair loss for over a decade. Dutasteride, a dual 5-alpha reductase inhibitor (blocking both type I and type II isoenzymes, compared to finasteride's type II selectivity), was FDA-approved for benign prostatic hyperplasia but used off-label for hair loss. Clinicians suspected it might work better given its broader enzyme blockade and longer half-life. What was missing was a properly powered randomized comparison in a large population. Eun et al. (2010) set out to fill that gap.

Who Was Enrolled

The trial recruited 917 men aged 20 to 50 with clinical androgenetic alopecia (Hamilton-Norwood types III through V). All participants were Korean. The study excluded men who had used finasteride or minoxidil within six months, those with significant medical comorbidities, and those with hair loss from other causes. This was a relatively homogeneous population, which strengthened internal validity but raised questions about generalizability to other ethnic groups.

What They Were Given

No published trial has characterized the stated randomized, dose-ranging comparison of dutasteride, finasteride, and placebo for androgenetic alopecia.

All capsules were identical in appearance. Neither the patients nor the investigators assessing outcomes knew which treatment was assigned, making this a double-blind parallel-group trial.

How Hair Growth Was Measured

The primary endpoint was the change from baseline in target-area hair count (TAHC) within a defined 1-inch circular area on the vertex scalp. Investigators used macrophotography with a dot tattoo to ensure the same scalp region was measured at each visit. Hair counts were performed by trained evaluators blinded to treatment assignment.

Secondary endpoints included investigator assessments of global improvement, patient self-assessment, and hair-width measurements.

The HealthRX.com Efficacy Interpretation Framework

To put the Eun results in proper context, we apply a three-lens analysis: absolute hair count difference, clinical perceptibility threshold, and comparative effect size versus placebo.

Lens 1: Absolute numbers. The dutasteride 0.5 mg group gained approximately 12.2 more hairs per cm² than finasteride at 24 weeks. This is a statistically significant difference (p < 0.05).

Lens 2: Clinical perceptibility. Research on visual density thresholds suggests that differences below approximately 20 hairs/cm² are difficult for untrained observers to detect. The dutasteride-over-finasteride advantage, while real, sits near the border of what patients would notice without direct measurement.

Lens 3: Effect size versus placebo. Both active drugs substantially outperformed placebo. Dutasteride 0.5 mg produced roughly 100 additional hairs in the target area versus placebo at week 24, while finasteride produced roughly 75 to 80 additional hairs. Both drugs clearly work. The question is whether the incremental advantage of dutasteride justifies the switch for a given patient.

Values approximate from published data; exact numbers vary by analysis method and subgroup.

Safety Findings at 24 Weeks

Adverse event rates were similar across the dutasteride 0.5 mg and finasteride groups. The most commonly reported issues were decreased libido, erectile dysfunction, and ejaculatory disorders. Rates in both groups were low (typically under 5%) and comparable.

The dutasteride 2.5 mg arm showed slightly higher rates of sexual side effects, which is consistent with the dose-response relationship seen in prostate studies. The FDA label for dutasteride (Avodart) for BPH lists similar adverse events drawn from longer-duration trials.

One important caveat: 24 weeks is too short to assess long-term safety differences. Dutasteride's half-life is approximately five weeks (compared to six to eight hours for finasteride), meaning the drug persists in tissue for months after discontinuation. Any side effects are correspondingly slower to resolve.

What the Trial Did Not Show

Several limitations deserve direct acknowledgment:

Short duration. Hair loss is a chronic condition. Twenty-four weeks captures early regrowth but misses the plateau and long-term maintenance phase. The phase III finasteride trials ran for two to five years and showed that peak benefit occurs around 12 to 24 months.

Single ethnicity. All 917 participants were Korean men. Androgen metabolism and hair follicle characteristics vary across populations. While the mechanism of 5-alpha reductase inhibition is universal, the magnitude of response may differ in non-Asian cohorts.

No minoxidil combination arm. Most real-world patients use combination therapy. This trial tested monotherapy only.

Industry funding. GlaxoSmithKline (the maker of dutasteride) sponsored the study. The investigators disclosed this appropriately, but it is relevant context for interpretation.

No patient-reported quality-of-life data. The trial measured hairs, not satisfaction. A statistically significant difference in hair count does not automatically translate to a meaningful difference in how patients feel about their hair.

Where This Fits in Clinical Practice Today

The Japanese Dermatological Association guidelines (2017 update) give dutasteride a grade A recommendation for male AGA, citing this trial among others. In South Korea and Japan, dutasteride is approved specifically for AGA. In the United States and Europe, it remains off-label for hair loss, prescribed at clinician discretion.

No published trials have established that switching from finasteride to dutasteride after an inadequate response provides additional benefit. Dutasteride may persist longer after stopping, and long-term safety data for hair loss remain limited.

Clinicians weighing this switch should also consider the Olsen et al. 2006 dose-response study, which demonstrated dutasteride's dose-dependent efficacy and supported the 0.5 mg dose as the optimal balance between efficacy and tolerability.

The Bottom Line for Patients

Dutasteride 0.5 mg grows more hair than finasteride 1 mg over six months. The difference is statistically significant and consistent across measurement methods. Whether that difference is large enough to matter to you depends on your starting point, your tolerance for a drug with a longer half-life, and whether finasteride alone is giving you adequate results.

Frequently asked questions

›Is dutasteride FDA-approved for hair loss?

No. Dutasteride (brand name Avodart) is FDA-approved only for benign prostatic hyperplasia. Its use for androgenetic alopecia is off-label in the US and Europe. It is approved for AGA in South Korea and Japan.

›How much better is dutasteride than finasteride for hair regrowth?

In this trial, dutasteride 0.5 mg produced roughly 15-20% more hair regrowth than finasteride 1 mg at 24 weeks. Both drugs substantially outperformed placebo. The incremental benefit of dutasteride is real but modest.

›Does dutasteride have more side effects than finasteride?

At the 0.5 mg dose studied here, sexual side effect rates were comparable to finasteride 1 mg over 24 weeks. The key practical difference is dutasteride's much longer half-life (5 weeks vs 6-8 hours), meaning side effects take longer to resolve after stopping.

›How long does it take to see results from dutasteride?

Most patients in this trial showed measurable improvement by week 12, with continued gains through week 24. Based on related trials, peak efficacy likely occurs between 12 and 24 months of continuous use.

›Can you take dutasteride and minoxidil together?

Yes. This trial did not test combination therapy, but in clinical practice many dermatologists combine oral dutasteride with topical minoxidil. The mechanisms are complementary (hormonal blockade plus vasodilation/follicle stimulation).

›Were all patients in this study Asian?

Yes, all 917 participants were Korean men. This is a valid limitation when extrapolating results to other populations, though the underlying pharmacology of 5-alpha reductase inhibition applies universally.

›What dose of dutasteride is used for hair loss?

The standard off-label dose is 0.5 mg daily, which is the same dose used for prostate enlargement. This trial tested multiple doses and found 0.5 mg provided a strong efficacy signal with a safety profile similar to finasteride.

›Should I switch from finasteride to dutasteride?

Consider switching if you have used finasteride consistently for at least 12 months without satisfactory results. Discuss with your prescriber the longer half-life and off-label status. For patients responding well to finasteride, switching may not provide enough additional benefit to justify the change.

›How long was this trial?

Twenty-four weeks (six months). This is adequate to demonstrate early efficacy but too short to assess long-term durability or rare long-term adverse events.

›Is this the largest dutasteride vs finasteride hair loss study?

Yes. With 917 participants across multiple dose arms, this remains one of the largest randomized comparisons of these two drugs for androgenetic alopecia published to date.

References

1. Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252-258. PubMed
2. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5-alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023. PubMed
3. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589. PubMed
4. Dutasteride (Avodart) prescribing information. U.S. Food and Drug Administration. FDA Label
5. Kinoshita-Ise M, Saceda-Corralo D, Shapiro J. Japanese Dermatological Association guidelines for androgenetic alopecia (2017 update). J Dermatol. 2019;46(2):e68-e69. PubMed